What are the unmet needs in the treatment of PNH despite eculizumab?

Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ... ALL prescribers and dispensing sites for ULTOMIRIS or SOLIRIS MUST be certified in the new, combined ULTOMIRIS and SOLIRIS REMS. You can certify here, or; You ... Apr 1, 2024 ... SOLIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections. SOLIRIS increases ... Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. ... Eculizumab has a long duration of ... Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. It inhibits the cleavage of C5 into C5a and C5b and hence inhibits ... This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Soliris ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ... May 3, 2019 ... In an open-label study involving 14 patients with highly clinically active, AQP4-IgG–positive disease, the use of eculizumab reduced the frequency of relapse. Feb 7, 2024 ... Eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive refractory generalized myasthenia gravis (gMG). Aetna considers eculizumab, or its biosimilar, medically necessary for any of the following indications when criteria are met: